New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model

Vaccine

Volumn 27, Issue 8, 2009, Pages 1230-1241

  Florindo, H F ^a,b   Pandit, S ^b   Goncalves L M D ^a,c   Alpar, H O ^b   Almeida, A J ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

Author keywords

Mucosal vaccine; Nanospheres; Poly(lactic acid); Strangles

Indexed keywords

ALGINIC ACID; BACTERIAL ANTIGEN; BACTERIAL VACCINE; CHITOSAN; DRUG CARRIER; GLYCOLCHITOSAN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NANOPARTICLE; NANOSPHERE; OLEIC ACID; POLYLACTIC ACID; POLYMER; POLYVINYL ALCOHOL; SPERMINE; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; FEMALE; HUMORAL IMMUNITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; STRANGLES; STREPTOCOCCUS EQUI; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; EQUIDAE; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; LACTIC ACID; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYMERS; SPLEEN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS EQUI;

EID: 58749108436     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.004     Document Type: Article

References (45)

1. Breiman R., and Silverblatt F. Systemic Streptococcus equi infection in a horse handler-a case of human strangles. West J Med 145 3 (1986) 385-386
2. Welsayed S., Hammerberg O., Massey V., and Hussain Z. Streptococcus equi subspecies equi (Lancefield group C) meningitis in a child. Clin Microbiol Infect 9 8 (2003) 869-872
3. Sweeney C.R., Timoney J.F., Newton J.R., and Hines M.T. Streptococcus equi infections in horses: guidelines for treatment, control, and prevention of strangles. J Vet Intern Med 19 (2005) 123-134
4. Waller A.S., and Jolley K.A. Getting a grip on strangles: recent progress towards improved diagnostics and vaccines. Vet J 173 3 (2007) 492-501
5. Flock M., Jacobsson K., Frykberg L., Hirst T.R., Franklin A., Guss B., et al. Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses. Infect Immun 72 6 (2004) 3228-3236
6. Harrington D.J., Greated J.S., Chanter N., and Sutcliffe I.C. Identification of lipoprotein homologues of pneumococcal PsaA in the equine pathogens Streptococcus equi and Streptococcus zooepidemicus. Infect Immun 68 10 (2000) 6048-6051
7. Hamilton A., Robinson C., Sutcliffe I., Slater J., Maskell D.J., Davis-Poynter N., et al. Mutation of the maturase lipoprotein attenuates the virulence of Streptococcus equi to a greater extent than does loss of general lipoprotein lipidation. Infect Immun 74 12 (2006) 6907-6919
8. Sheoran A.S., Artiushin S., and Timoney J.F. Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin. Vaccine 20 (2002) 1653-1659
9. Timoney J., and Eggers D. Serum bactericidal responses to Streptococcus equi of horses following infection or vaccination. Equine Vet J 17 (1985) 306-310
10. Nally J., Artiushin S., Sheoran A., Burns P.J., Simon B., Gilley R.M., et al. Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system. Vaccine 19 (2001) 492-497
11. Lemoine D., Deschuyteneer M., Hogge F., and Preat V. Intranasal immunization against influenza virus using polymeric particles. J Biomater Sci Polym Ed 10 (1999) 805-825
12. Almeida A.J., Alpar H.O., and Brown M.R.W. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol 45 (1993) 198-203
13. Eyles J.E., Spiers I.D., Williamson E.D., and Alpar H.O. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal, intra-muscular administration of microsphere co-encapsualted Yersinia pestis sub-unit vaccines. Vaccine 16 (1998) 2000-2009
14. Singh M., and O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res 19 6 (2002) 715-728
15. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24 19 (2006) 4201-4211
16. Borges O., Borchard G., Verhoef jC, Sousa A., and Junginger H.E. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299 (2005) 155-166
17. Sugita Y., Takao K., Toyama Y., and Shirahatal A. Enhancement of intestinal absorption of macromolecules by spermine in rats. Amino Acids 33 (2007) 253-260
18. Ascarateil S., and Dupuis L. Surfactants in vaccine adjuvants: description and perspectives. Vaccine 24S2 (2006) S2/83-S2/85
19. Florindo H.F., Pandit S., Lacerda L., Gonçalves L.M.D., Alpar H.O., and Almeida A.J. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ε-caprolactone-based nanoparticles. Biomaterials 30 (2009) 879-891
20. Florindo H., Pandit S., Gonçalves L., Alpar H., and Almeida A. S. equi antigens adsorbed onto surface modified poly-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 26 (2008) 4168-4177
21. Towbin H., Staehlin T., and Gordin J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications. Proc Natl Acad Sci USA 76 (1979) 4350-4354
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 1-2 (1983) 55-63
23. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G., Li J., and Mottram P. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 (2004) 3148-3154
24. Lee E.S., Park K., Park I.S., and Na K. Glycol chitosan as a stabilizer for protein encapsulated into poly(lactide-co-glycolide) microparticle. Int J Pharm 338 (2007) 310-316
25. Johansen P., Gander B., Merkle H., and Sesardic D. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol 18 (2000) 203-211
26. Johansen P., Men Y., Merkle H.P., and Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50 1 (2000) 129-146
27. Venkataprasad N., Coombes A.G., Singh M., Rohde M., Wilkinson K., Hudecz F., et al. Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 17 15-16 (1999) 1814-1819
28. Azevedo A.F., Galhardas J., Cunha A., Cruz P., Goncalves L.M., and Almeida A.J. Microencapsulation of Streptococcus equi antigens in biodegradable microspheres and preliminary immunisation studies. Eur J Pharm Biopharm 64 2 (2006) 131-137
29. Gutierro I., Herandez R., Igartua M., Gascon A., and Pedraz J. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21 (2002) 67-77
30. Donovan M.D., and Huang Y. Large molecule and particulate uptake in nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv Rev 29 (1998) 147-155
31. Nixon D., Hioe C., Chen P., Bian Z., Kuebler P., Li M.L., et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 14 (1996) 1523-1530
32. Song C., Labshasetwar V., Murphy H., Qu X., Humphrey W.R., Shebuski J., et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release 43 (1997) 197-212
33. Katare Y., Muthukumaran T., and Panda A. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 301 (2005) 149-160
34. Eyles J., Bramwell V., Williamson E., and Alpar H. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19 (2001) 4732-4742
35. Sun H., Pollock K., and Brewer J. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21 (2003) 849-855
36. Hordnes K., Tynning T., Brown T., Haneberg B., and Jonsson R. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15 (1997) 1244-1251
37. Rojas-Hernandez S., Rodriguez-Monroy M., Lopez-Revilla R., Resendiz-Albor A., and Moreno-Fierros L. Intranasal co-administration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect Immun 72 (2004) 4368-4375
38. Baudner B.C., Giuliani M.M., Verhoef J.C., Rappuoli R., Junginger H.E., and Giudice G.D. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21 25-26 (2003) 3837-3844
39. Dodane V., Amin K.M., and Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int J Pharm 182 (1999) 21-32
40. Jiang W., Gupta R., Deshpande M., and Schwendeman S. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57 (2005) 391-410
41. Yanagita M., Hiroi T., Kitagaki N., Hamada S., Ito H., Shimauchi H., et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol 162 (1999) 3569-3575
42. Ito R., Ozaki Y., Yoshikawa T., Hasegawa H., Sato Y., and Suzuki Y. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21 (2003) 2362-2371
43. Estevan M., Irache J., Grillo M., Blasco J., and Gamazo C. Encapsulation of antigenic extracts of Salmonella enterica serovar Abortusovis into polymeric systems and efficacy as vaccines in mice. Vet Microbiol 118 (2006) 124-132
44. Ludewig B., Barchiesi F., Pericin M., Zinkernagel R., Hengartner H., and Schwendener R. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19 (2000) 23-32
45. Moschos S., Bramwell V., Somavarapu S., and Alpar H. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine 24 8 (2006) 1081-1086